Union européenne - norvégien - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - belantamab mafodotin - multippelt myelom - antineoplastiske midler - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.

Union européenne - norvégien - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, fluticasone propionate - astma - legemidler for obstruktive sykdommer i luftveiene, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Union européenne - norvégien - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - astma - legemidler for obstruktive sykdommer i luftveiene, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Union européenne - norvégien - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - legemidler som brukes i diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 og 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

Union européenne - norvégien - EMA (European Medicines Agency)

eli lilly nederland b.v. - duloksetin - diabetiske neuropatier - psychoanaleptics, - behandling av diabetisk perifer neuropatisk smerte. ariclaim er indisert hos voksne.

Union européenne - norvégien - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multippel sklerose - selektive immunosuppressiva - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Union européenne - norvégien - EMA (European Medicines Agency)

viiv healthcare b.v. - maraviroc - hiv-infeksjoner - antivirale midler til systemisk bruk - celsentri, in combination with other antiretroviral medicinal products, is indicated for treatment experienced adults, adolescents and children of 2 years of age and older and weighing at least 10 kg infected with only ccr5-tropic hiv-1 detectable,.

Union européenne - norvégien - EMA (European Medicines Agency)

janssen-cilag international n.v.   - decitabine - leukemi, myeloid - antineoplastiske midler - behandling av voksne pasienter med nylig diagnostisert de novo eller sekundær akutt myeloide leukemi (aml), i henhold til who-klassifikasjonen, som ikke er kandidater for standard induksjonskreoterapi.

Union européenne - norvégien - EMA (European Medicines Agency)

recordati ireland ltd. - lidokain, prilocaine - seksuell dysfunksjon, fysiologisk - anestetika - behandling av primær prematur utløsning i voksne menn.

Union européenne - norvégien - EMA (European Medicines Agency)

eisai gmbh - eribulin - breast neoplasms; liposarcoma - antineoplastiske midler - halaven monoterapi er indisert for behandling av pasienter med lokalt avansert eller metastatisk brystkreft som har utviklet seg etter minst ett kjemoterapeutisk regime for avansert sykdom (se avsnitt 5. tidligere behandling bør ha inkludert en antracyklin og en taxan med mindre pasienter ikke var egnet for disse behandlingene. halaven er indisert for behandling av voksne pasienter med inoperabel liposarcoma som har fått før anthracycline inneholder terapi (med mindre uegnet) for avansert eller metastatisk sykdom (se kapittel 5.